Eris Lifesciences Ltd.
NSE: ERIS · Pharmaceuticals
Snapshot
Unlock Eris Lifesciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of branded formulations. The company operates across a diverse range of therapeutic areas, including cardiovascular, anti-diabetes, neurology, and dermatology.
Business Model
The company generates revenue through the sale of branded pharmaceutical formulations across various therapeutic segments. It focuses on high-growth chronic and sub-chronic therapy areas within the Indian domestic market.
Growth Outlook
Growth is driven by the expansion of its product portfolio into specialized therapeutic segments such as in-vitro fertilization and cosmetology. The company continues to leverage its established distribution network to increase market penetration in India.
Key Risks
- Regulatory Risk. The company is subject to stringent price controls and regulatory oversight by the National Pharmaceutical Pricing Authority in India.
- Competitive Intensity. The Indian pharmaceutical market is highly fragmented and competitive, which may exert pressure on profit margins.
- Product Concentration. Reliance on specific therapeutic segments could impact financial performance if there are shifts in medical prescription trends or market demand.
Start your research today
Unlock AI insights, financials, peers and live data on Eris Lifesciences Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,230 Cr
TTM · consolidated
NET PROFIT
₹666 Cr
TTM · consolidated
EPS
₹47.02
TTM · consolidated
RETURN ON EQUITY
19.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.5%
TTM · consolidated
P/E
28.1x
Q1 FY27 · consolidated
EV/EBITDA
17.9x
Q1 FY27 · consolidated
EBITDA MARGIN
35.5%
TTM · consolidated
NET PROFIT MARGIN
16.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.6%
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Eris Lifesciences Ltd.ERIS | ₹18,314 Cr | 28.11 | 17.93 | 9.7% | 35.5% | 19.7% | 15.5% | -25.1% |
Shilpa Medicare LimitedSHILPAMED | ₹18,857 Cr | 63.10 | 40.08 | 27.9% | 28.9% | 12.0% | 14.2% | +14.5% |
Onesource Specialty Pharma Ltd.ONESOURCE | ₹17,630 Cr | -362.69 | 53.51 | 27.2% | 22.8% | -0.8% | 0.9% | -18.2% |
Cohance Lifesciences Ltd.COHANCE | ₹17,468 Cr | 164.24 | 50.50 | 41.2% | 16.3% | 2.1% | 3.5% | -49.2% |
AstraZenca Pharma India Ltd.ASTRAZEN | ₹17,360 Cr | 102.34 | 65.98 | 31.1% | 10.5% | 20.6% | 25.7% | -23.8% |
Alembic Pharmaceuticals Ltd.APLLTD | ₹15,886 Cr | 22.91 | 13.84 | 14.1% | 15.8% | 12.7% | 14.3% | -15.8% |
As of Q1 FY27
Financials
Eris Lifesciences Ltd.
NSE: ERIS · Pharmaceuticals
Snapshot
Unlock Eris Lifesciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of branded formulations. The company operates across a diverse range of therapeutic areas, including cardiovascular, anti-diabetes, neurology, and dermatology.
Business Model
The company generates revenue through the sale of branded pharmaceutical formulations across various therapeutic segments. It focuses on high-growth chronic and sub-chronic therapy areas within the Indian domestic market.
Growth Outlook
Growth is driven by the expansion of its product portfolio into specialized therapeutic segments such as in-vitro fertilization and cosmetology. The company continues to leverage its established distribution network to increase market penetration in India.
Key Risks
- Regulatory Risk. The company is subject to stringent price controls and regulatory oversight by the National Pharmaceutical Pricing Authority in India.
- Competitive Intensity. The Indian pharmaceutical market is highly fragmented and competitive, which may exert pressure on profit margins.
- Product Concentration. Reliance on specific therapeutic segments could impact financial performance if there are shifts in medical prescription trends or market demand.
Start your research today
Unlock AI insights, financials, peers and live data on Eris Lifesciences Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,230 Cr
TTM · consolidated
NET PROFIT
₹666 Cr
TTM · consolidated
EPS
₹47.02
TTM · consolidated
RETURN ON EQUITY
19.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.5%
TTM · consolidated
P/E
28.1x
Q1 FY27 · consolidated
EV/EBITDA
17.9x
Q1 FY27 · consolidated
EBITDA MARGIN
35.5%
TTM · consolidated
NET PROFIT MARGIN
16.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.6%
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27